IMMUNITYBIO, INC. Finite-Lived Intangible Assets, Net
IMMUNITYBIO, INC. (IBRX) had Finite-Lived Intangible Assets, Net of $11.91 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-05-07
- 2026-03-31: Finite-Lived Intangible Assets, Net $11.91M.
- 2025-12-31: Finite-Lived Intangible Assets, Net $12.99M.
- 2025-09-30: Finite-Lived Intangible Assets, Net $13.53M.
- 2025-06-30: Finite-Lived Intangible Assets, Net $13.51M.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2026-03-31 | $11.91M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $12.99M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $13.53M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $13.51M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $14.02M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $14.53M 10-K · filed 2025-03-03 |
| 2024-09-30 | $15.04M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $15.55M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $16.06M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $16.57M 10-K · filed 2024-03-19 |
| 2023-09-30 | $17.08M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $17.59M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $18.10M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $18.61M 10-K · filed 2024-03-19 |
| 2015-12-31 | $7.29M 10-K · filed 2016-03-30 |
| 2014-12-31 | $3.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |